Advanced age (≥80 years) significantly increased the probability of achieving target anti-Xa levels with enoxaparin at lower weight-adjusted doses (0.66–0.72 mg/kg/day) versus younger patients (<80 years, 0.87–0.98 mg/kg/day), while renal function (eGFR <60 vs ≥60 mL/min/1.73 m2) showed no significant impact.
Observational (n=135)
No
Does age or renal function influence the attainment of target anti-Xa levels in Asian patients receiving enoxaparin?
135 Asian patients receiving enoxaparin therapy with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m².
Enoxaparin therapy (weight-adjusted dosing)
Patients aged < 80 years versus ≥ 80 years, and patients with eGFR < 60 mL/min versus ≥ 60 mL/min
Attainment of target anti-Xa levelssurrogate
In Asian patients with eGFR ≥ 30 mL/min/1.73 m², advanced age (≥ 80 years) rather than mild-to-moderate renal impairment dictates the need for lower enoxaparin doses to achieve target anti-Xa levels.
p-value: p=<0.05 for age effect, no significant difference for renal function
Objective: To investigate the roles of age and renal function in optimizing enoxaparin dosage for achieving target anti-Xa levels in Asian patients. Methods: A total of 135 patients subjected to enoxaparin therapy were retrospectively enrolled. Baseline demographic characteristics, clinical indicators, and laboratory test results were collected. The distribution patterns of weight-adjusted doses and anti-Xa levels were analyzed. Dose-response curves were employed to evaluate the probability of achieving therapeutic anti-Xa levels in different age groups (< 80 years vs ≥ 80 years) and estimated glomerular filtration rate (eGFR) categories (eGFR < 60 mL/min vs ≥ 60 mL/min). Results: The dose distribution revealed discrepancies between actual weight-adjusted doses and manufacturer-recommended doses in some patients. Age significantly influenced the attainment of target anti-Xa levels, whereas renal function exhibited no significant impact. Dose-response curves demonstrated that patients aged ≥ 80 years required lower doses to achieve 90– 95% target anti-Xa levels compared to those < 80 years. No significant difference was observed in target attainment between patients with eGFR < 60 mL/min and those with eGFR ≥ 60 mL/min. Conclusion: Within the range of eGFR ≥ 30 mL/min/1.73 m 2 , advanced age, rather than mild-to-moderate renal impairment, emerged as the critical factor for achieving target anti-Xa levels with enoxaparin in Asian patients. Patients aged ≥ 80 years required lower doses compared to younger patients. These findings still need prospective validation. Keywords: enoxaparin, Asian patients, anti-Xa levels, age, renal function
Building similarity graph...
Analyzing shared references across papers
Loading...
Peng et al. (Sun,) conducted a observational in Asian adult patients (≥18 years) treated with enoxaparin for venous thromboembolism or high-risk thrombotic conditions with eGFR ≥30 mL/min/1.73 m2 (n=135). Enoxaparin vs. No intervention (observational comparison by age and renal function subgroups) was evaluated on Probability of achieving target anti-Xa levels (0.4–1.0 IU/mL) (p=<0.05 for age effect, no significant difference for renal function). Advanced age (≥80 years) significantly increased the probability of achieving target anti-Xa levels with enoxaparin at lower weight-adjusted doses (0.66–0.72 mg/kg/day) versus younger patients (<80 years, 0.87–0.98 mg/kg/day), while renal function (eGFR <60 vs ≥60 mL/min/1.73 m2) showed no significant impact.
synapsesocial.com/papers/69a767bbbadf0bb9e87e2201 — DOI: https://doi.org/10.2147/cpaa.s576067
Wenxing Peng
Shuran Yang
Capital Medical University
Ying Dai
Fujian Medical University
Clinical Pharmacology Advances and Applications
Chinese Academy of Medical Sciences & Peking Union Medical College
Capital Medical University
Wenzhou Medical University
Building similarity graph...
Analyzing shared references across papers
Loading...
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: